Antibiotic-associated diarrhea: state-of-the-art
Abstract
The aim of review. To analyse modern concepts on antibiotic-associated diarrhea, to determine its place in the pattern of total morbidity.
Key points. Wide antibiotic application in all sections of medicine along with beneficial action has series of essential side effects, including antibiotic-associated diarrhea. Its extreme and most severe manifestation is pseudomembranous colitis, caused by toxin-producing Clostridium difficile strains. This etiological agent in modern world has got significant association with hospitals and assisted-care facilities, therefore it can spread in out-patient conditions as well at the present time. Mutations resulting in antibiotic resistance, increasing toxin production or promoting sporulation, considerably increase virulence and prevalence of these opportunistic microorganisms.
Conclusion. The further studies on development of effective prophylactic and treatment methods of antibiotic-associated diarrhea are required, especially for most severe complication — pseudomembranous colitis. It is necessary to limit application of antibiotics, develop strict indications to their application.
About the Authors
D. V. Piliev
Federal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian Federation
Russian Federation
Russian Federation
Piliev Dmitry V — post-graduate student, department of oncology and surgery of the colon
123423, Moscow, Salyam Adilya street, 2
S. I. Achkasov
Federal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian Federation
Russian Federation
Russian Federation
Achkasov Sergey I — MD, PhD, professor, head of department of oncology and surgery of the colon
123423, Moscow, Salyam Adilya street, 2
T. K. Korneva
Federal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian Federation
Russian Federation
Russian Federation
O. I. Sushkov
Federal state-funded institution «State Scientific Center of Coloproctology» Ministry of heathcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Бондаренко В.М., Учайкин В.Ф., Мурашова А.О., Абрамов Н.А. Дисбиоз: современные возможности профилактики и лечения. М.; 1995. 68 с.
2. Воробьев А.А., Быков А.С. Атлас по медицинской микробиологии, вирусологии и иммунологии. М.: Медицинское информационное агентство; 2003. 236 с.
3. Воробьев Г.И., Жученко А.П., Бирюков О.М., Пикунов Д.Ю. Псевдомембранозный колит с вовлечением червеобразного отростка и тонкой кишки, осложнившийся токсической дилатацией (Клиническое наблюдение). Колопроктология 2010; 2(32):50-4.
4. Дмитриева Н.В., Петухова И.Н. Послеоперационные инфекционные осложнения: Практическое руководство. М.: Практическая медицина; 2013. 422 с.
5. Дуда А.К., Окружнов Н.В. Антибиотикоассоциированные диареи и псевдомембранозный колит: диагностика и рациональная терапия. Семейная медицина 2012; 5:116-22.
6. Кайзер А.М. Колоректальная хирургия: Пер. с англ. Е.Г. Рыбакова / Под ред. Ю.А. Шелыгина. Изд-во Панфилова, 2011. 751 с.
7. Лузина Е.В. Антибиотикоассоциированная диарея. Сибирский медицинский журнал 2009; 2:122-4.
8. Малов В.А., Пак С.Г., Беликов Д.В. Псевдомембранозный колит. Лечащий врач 1999; 2-3. http://www. lvrach.ru/1999/02-03/4527414/
9. Меньшиков В.В. Методики клинических лабораторных исследований: Справочное пособие. Т 3; 2009:64-82.
10. Осипенко М.Ф., Бикбулатова Е.А. Антибиотикоассоциированная диарея, подходы к диагностике и лечению. Фарматека 2007; 13:89-93.
11. Петрук М.Н., Нешитов С.П. Псевдомембранозный колит. Хирургия 2009; 4:55-60.
12. Пикунов Д.Ю., Рыбаков Е.Г., Головенко О.В. Псевдомембранозный колит. Колопроктология 2010; 2(32):5560.
13. Санитарно-эпидемиологические требования к организациям, осуществляющим медицинскую деятельность. САНПИН 2.1.3.2630-10. Утверждены Постановлением Главного санитарного врача РФ от 18 мая 2010 г. № 58.
14. Секачева М.И. Антибиотикоассоциированная диарея. Сonsilium Мedicum. Гастроэнтерология 2007; 2:39-42.
15. Шевяков М.А. Антибиотикоассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики. Антибиотики и химиотерапия 2004; 49(10):269.
16. Шендеров Б.А. Медицинская микробная экология и функциональное питание. Т 2. М.; 1998. 704 с.
17. Шульпекова Ю.О. Антибиотикоассоциированная диарея. Рус мед журн 2007; 15(6):1-6.
18. Carignan A, Allard C, Pépin J, Cossette B, Nault V, Valiquette L. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008; 46:1838-43.
19. Chang H.Y., Min M.C., Seong K.B., Ok S.B. Risk factors for the development of Clostridium difficileassociated colitis after colorectal cancer surgery. J Korean Soc Coloproctol 2010; 26 (Suppl. 5):329-33.
20. George W.L. Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects. Rev Infect Dis 1984; 6 (Suppl. 1):208-13.
21. Greenstein A.J., Byrn J.C., Zhang L.P., Swedish K.A., Jahn A.E., Divino C.M. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008; 143 (Suppl. 5):623-9.
22. Hogenauer C, Hammer H.F., Krejs G.J., Reisinger E.C. Mechanism and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27:702-10.
23. Hookman P, Barkin J.S. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15 (Suppl. 13):1554-80.
24. Jump R.L., Pultz M.J., Donskey C.J. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 2007; 51:2883-7.
25. Kawecki D, Chmura A, Pacholczyk M, et al. Detection of Clostridium difficile in stool samples from patients in the early period after liver transplantation. Transplant Proc 2007; 39:2812-5.
26. Kelly C.P. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18 (Suppl. 6):21-7.
27. Kelly C.P., LaMont J.T. Clostridium difficile — more difficult than ever. N Engl J Med 2008; 359 (Suppl. 18):1932-40.
28. Kwok C.S., Arthur A.K., Anibueze C.I., Singh S, Cavallazzi R, Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol 2012; 107 (Suppl. 7):1011-9.
29. Louie T.J., Miller M.A., Crook D.W., Lentnek A, Bernard L, High K.P., Youe-Kong S, Gorbach S.L. Effect of age on treatment outcomes in Clostridium difficile infection. JAGS 2013; 61 (Suppl. 2):222-30.
30. McDonald L.C., Owings M, Jernigan J.B. Clostridium difficile infection in patients discharged from US shortstay hospitals, 1996 to 2003. Emerg Infect Dis 2006; 12:409-15.
31. Metzger R, Swenson B.R., Bonatti H, Hedrick T.L., Hranjec T, Popovsky K.A., Pruett T.L., Sawyer R.G. Identification of risk factors for the development of Clostridium difficile-associated diarrhea following treatment of polymicrobial surgical infections. Ann Surg 2010; 251 (Suppl. 4):722-7.
32. Mullane K.M., Miller M.A., Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53 (Suppl. 5):440-47.
33. Owens R.C., Donskey C.J., Gaynes R.P., Loo V.G., Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl. 1):19-31.
34. Plummer S, Weaver M.A., Harris J.C., Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhea. Int Microbiol 2004; 7 (Suppl. 1):59-62.
35. Polage C.R., Chin D.L., Leslie J.L., Tang J, Cohen S.H., Solnick J.V. Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis 2012; 74:36973.
36. Scheurer D. Diagnostic and treatment delays in recurrent Clostridium difficile-associated disease. J Hosp Med 2008; 3:156-9.
37. Sonnenberg A. Similar geographic variations of mortality and hospitalization associated with IBD and Clostridium difficile colitis. Inflamm Bowel Dis 2010; 16 (Suppl. 3):487-93.
38. Spencer R.C. The role of antimicrobial agents in the aetiology of Clostridium difficile associated disease. J Antimicrob Chemother 1998; 41:21-7.
39. Wilson M.Z., Hollenbeak C.S., Stewart D.B. The impact of Clostridium difficile colitis following closure of a diverting loop ileostomy: results of a matched cohort study. Colorectal Dis 2013; 15 (Suppl. 8):974-81.
40. www.clinvest.ru // Качественная клиническая практика. Сайт журнала Good Clinical Practice http://www. clinvest.ru/news-det.php?nid=1633
41. Yearsley K.A., Gilby L.J., Ramadas A.V., Kubiak E.M., Fone D.L., Allison M.C. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment Pharmacol Ther 2006; 24:613-9.
42. Zar F.A., Bakkanagari S.R., K M L S T Moorthi, Davis M.B. A Comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
Review
For citations:
Piliev D.V., Achkasov S.I., Korneva T.K., Sushkov O.I. Antibiotic-associated diarrhea: state-of-the-art. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(5):54-62. (In Russ.)
Views:
211
Email this article 
